2023
Associations of Early Completion of Advance Directives With Key End-of-Life Quality Measures: Analysis of an ASCO Quality Oncology Practice Initiative Patient Cohort
Power S, Bickel K, Chen R, Chiang A, Garrett-Mayer L, Makhoul I, Mougalian S, Shapiro C, Siegel R, Smith C, Rocque G, Kozlik M, Crist S, Kamal A. Associations of Early Completion of Advance Directives With Key End-of-Life Quality Measures: Analysis of an ASCO Quality Oncology Practice Initiative Patient Cohort. JCO Oncology Practice 2023, 19: e520-e526. PMID: 36669136, DOI: 10.1200/op.22.00464.Peer-Reviewed Original ResearchConceptsDays of lifeEmergency room visitsAD completionChemotherapy receiptRoom visitsAdvance directivesIntensive care unit admissionLife quality measuresCare unit admissionEOL quality measuresOutcomes of patientsIntensive care unitPatient-level dataChi-square testHigh rateUnit admissionHospice enrollmentCare unitOncology visitsPatient cohortPatient enrollmentPatientsCancer diagnosisVisitsQuality measures
2022
EP16.02-002 Circulating Tumor DNA (ctDNA) Changes in Patients With Lung Cancer from a Real-World Prospective Clinico-Genomic (PCG) Study
Chiang A, Kaur M, Assaf Z, Fine A, Zhao Y, Cao Y, Madison R, Oxnard G, Tolba K, Zuniga R, Lakhanpal S, Antic V, Bourla A, Schulze K. EP16.02-002 Circulating Tumor DNA (ctDNA) Changes in Patients With Lung Cancer from a Real-World Prospective Clinico-Genomic (PCG) Study. Journal Of Thoracic Oncology 2022, 17: s571-s572. DOI: 10.1016/j.jtho.2022.07.1033.Peer-Reviewed Original ResearchPlenary Session—The Patient Journey: Access to Cancer Care
Hammon D, Souza E, Chiang A, Shulman L, Kubal T. Plenary Session—The Patient Journey: Access to Cancer Care. Journal Of The National Comprehensive Cancer Network 2022, 20: 1-4. DOI: 10.6004/jnccn.2022.5011.Peer-Reviewed Original Research
2021
“The waiting is the worst”: Development of a next day access (NDA) program for patients with cancer.
Mougalian S, Shomsky L, Campos M, Chiang A. “The waiting is the worst”: Development of a next day access (NDA) program for patients with cancer. Journal Of Clinical Oncology 2021, 39: 205-205. DOI: 10.1200/jco.2020.39.28_suppl.205.Peer-Reviewed Original ResearchTreatment initiationMedian timeCancer CenterFirst visitNew patientsNew patient volumeSubsequent treatment initiationCommon reason patientsComprehensive cancer centerEstablishment of careStudy-Act cyclesNext-day appointmentsDays-1 yearOncologic consultationBrief anonymous surveyReasons patientsClinical reviewSubspecialty clinicsCancer carePatient satisfactionWorse outcomesBreast cancerRetrospective analysisTimely appointmentsPatients
2020
Development and evaluation of patient reported outcomes-based performance measures during chemotherapy.
Urick B, Stover A, Deal A, Jansen J, Chiang A, Cleeland C, Zylla D, Basch E. Development and evaluation of patient reported outcomes-based performance measures during chemotherapy. Journal Of Clinical Oncology 2020, 38: e19175-e19175. DOI: 10.1200/jco.2020.38.15_suppl.e19175.Peer-Reviewed Original ResearchHigh symptom burdenRelative riskSymptom burdenPhysical functioningCut pointsLow self-reported physical functioningSelf-reported physical functioningProportion of patientsEvaluation of patientsLower physical functioningOncology Care ModelShort formCut-point scoreChemotherapy cyclesSymptom controlCancer CenterSymptom SurveyMultiple symptomsCare modelPatientsGreater severityOutcome performance measuresSymptom itemsPRO itemsPrevalence
2019
Development and testing of patient-reported outcome performance measures (PRO-PMs) for oncology practice.
Stover A, Urick B, Deal A, Jansen J, Henson S, Miller R, Smith T, Scholle S, Chiang A, Cleeland C, Deutsch Y, Zylla D, Pitzen C, Snyder C, McNiff K, Krzyzanowska M, Spears P, Smith M, Geoghegan C, Basch E. Development and testing of patient-reported outcome performance measures (PRO-PMs) for oncology practice. Journal Of Clinical Oncology 2019, 37: 173-173. DOI: 10.1200/jco.2019.37.27_suppl.173.Peer-Reviewed Original ResearchOncology practiceSymptom managementOutcome performance measuresCancer typesCommunity oncology practicesRisk-adjustment variablesNational Quality ForumRisk-adjusted ratesActionable symptomsChemotherapy cyclesSymptom burdenInsurance typeInclusion criteriaLinear mixed modelingPractice variationGeneralized linear mixed modelingDay 5SymptomsQuality ForumPatientsRA variablesPractice levelMeaningful thresholdMulti-stakeholder consensusMixed modeling
2018
Standardizing goals of care (GoC) documentation for new patients with metastatic disease.
Kidwai W, Engelking C, Pyle J, Chiang A. Standardizing goals of care (GoC) documentation for new patients with metastatic disease. Journal Of Clinical Oncology 2018, 36: 26-26. DOI: 10.1200/jco.2018.36.34_suppl.26.Peer-Reviewed Original ResearchGOC discussionsGOC documentationPatient-centered cancer carePalliative care teamEligible patientsSmart phrasesMetastatic diseaseNursing assessmentPatient assessmentCancer careQuality improvement toolsCare teamMetastatic cancerThird visitNew patientsProvider timeCare documentationPatientsBusy practiceProvider capacityBaseline dataElectronic documentationProvidersImprovement toolsFacilitative strategiesFinal Results of a Phase I Prospective Trial Evaluating the Combination of Stereotactic Body Radiation Therapy (SBRT) with Concurrent Pembrolizumab in Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) or Melanoma
Campbell A, Herbst R, Gettinger S, Goldberg S, Kluger H, Chiang A, Lilenbaum R, Schalper K, Sowell R, Kaech S, Decker R. Final Results of a Phase I Prospective Trial Evaluating the Combination of Stereotactic Body Radiation Therapy (SBRT) with Concurrent Pembrolizumab in Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) or Melanoma. International Journal Of Radiation Oncology • Biology • Physics 2018, 102: s18-s19. DOI: 10.1016/j.ijrobp.2018.06.134.Peer-Reviewed Original ResearchSimple interventions to decrease use of chemotherapy in patients at the end of life.
Chiang A, Adelson K, Kapo J, Severino K, Lilenbaum R. Simple interventions to decrease use of chemotherapy in patients at the end of life. Journal Of Clinical Oncology 2018, 36: 181-181. DOI: 10.1200/jco.2018.36.30_suppl.181.Peer-Reviewed Original ResearchDays of lifeCourse of illnessEnd of lifeDay of deathGOC conversationsPrimary oncologistCare centerEarly palliative care referralPalliative care referralUse of chemotherapyPalliative care trainingChemotherapy utilizationCare referralPoor prognosisGOC discussionsCancer patientsUnnecessary treatmentGeneral oncologistsCare conversationsPost interventionPatientsChemotherapyMultidisciplinary teamPatient carePhysicians' skillsMA15.11 Real World Biomarker Testing and Treatment Patterns in Patients with Advanced NSCLC Receiving EGFR-TKIs
Chiang A, Fernandes A, Pavilack M, Wu J, Laliberté F, Duh M, Chehab N, Subramanian J. MA15.11 Real World Biomarker Testing and Treatment Patterns in Patients with Advanced NSCLC Receiving EGFR-TKIs. Journal Of Thoracic Oncology 2018, 13: s410-s411. DOI: 10.1016/j.jtho.2018.08.447.Peer-Reviewed Original ResearchDurability of brain metastasis response and overall survival in patients with non-small cell lung cancer (NSCLC) treated with pembrolizumab.
Goldberg S, Gettinger S, Mahajan A, Herbst R, Chiang A, Lilenbaum R, Jilaveanu L, Rowen E, Gerrish H, Komlo A, Wei W, Chiang V, Kluger H. Durability of brain metastasis response and overall survival in patients with non-small cell lung cancer (NSCLC) treated with pembrolizumab. Journal Of Clinical Oncology 2018, 36: 2009-2009. DOI: 10.1200/jco.2018.36.15_suppl.2009.Peer-Reviewed Original ResearchFinal results of a phase I prospective trial evaluating the combination of stereotactic body radiotherapy (SBRT) with concurrent pembrolizumab in patients with metastatic non-small cell lung cancer (NSCLC) or melanoma.
Campbell A, Herbst R, Gettinger S, Goldberg S, Kluger H, Chiang A, Lilenbaum R, Schalper K, Sowell R, Kaech S, Decker R. Final results of a phase I prospective trial evaluating the combination of stereotactic body radiotherapy (SBRT) with concurrent pembrolizumab in patients with metastatic non-small cell lung cancer (NSCLC) or melanoma. Journal Of Clinical Oncology 2018, 36: 9099-9099. DOI: 10.1200/jco.2018.36.15_suppl.9099.Peer-Reviewed Original Research
2017
1530PD Results of a randomized, placebo-controlled, phase 2 study of tarextumab (TRXT, anti-Notch2/3) in combination with etoposide and platinum (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC)
Daniel D, Rudin C, Hart L, Spigel D, Edelman M, Goldschmidt J, Bordoni R, Glisson B, Burns T, Dowlati A, Dy G, Beck T, Jotte R, Liu S, Kapoun A, Faoro L, Chiang A. 1530PD Results of a randomized, placebo-controlled, phase 2 study of tarextumab (TRXT, anti-Notch2/3) in combination with etoposide and platinum (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC). Annals Of Oncology 2017, 28: v540. DOI: 10.1093/annonc/mdx386.004.Peer-Reviewed Original Research
2016
Pneumonitis in non-small cell lung cancer (NSCLC) patients treated with programmed death 1 (PD1) axis inhibitors.
Gettinger S, Zhang X, Homer R, Possick J, Wurtz A, Goldberg S, Chiang A, Herbst R, Rubinowitz A. Pneumonitis in non-small cell lung cancer (NSCLC) patients treated with programmed death 1 (PD1) axis inhibitors. Journal Of Clinical Oncology 2016, 34: 9030-9030. DOI: 10.1200/jco.2016.34.15_suppl.9030.Peer-Reviewed Original ResearchUpdated results of phase 1b study of tarextumab (TRXT, anti-Notch2/3) in combination with etoposide and platinum (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC).
Chiang A, Rudin C, Spira A, Jotte R, Gadgeel S, Mita A, Hart L, Gluck W, Liu S, Kapoun A, Xu L, Hill D, Zhou L, Dupont J, Spigel D. Updated results of phase 1b study of tarextumab (TRXT, anti-Notch2/3) in combination with etoposide and platinum (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC). Journal Of Clinical Oncology 2016, 34: 8564-8564. DOI: 10.1200/jco.2016.34.15_suppl.8564.Peer-Reviewed Original ResearchMultidisciplinary process improvement to optimize oral chemotherapy safety.
Amport S, Adelson K, Fradkin M, Havriliak R, Harrison M, Abdelghany O, Kregling S, Wright J, Morrow B, Sterling R, Smith M, Esposito F, Stutsky M, Miller L, Lilenbaum R, Lyons C, Chiang A, Cohen H. Multidisciplinary process improvement to optimize oral chemotherapy safety. Journal Of Clinical Oncology 2016, 34: 134-134. DOI: 10.1200/jco.2016.34.7_suppl.134.Peer-Reviewed Original ResearchMedication assistance programsPatient educationOral chemotherapy agentsPatient phone callsMultidisciplinary care modelStandardized patient educationMultidisciplinary task forceAddress patients' concernsTherapy delayChemotherapy safetyAdherence monitoringParenteral chemotherapyPatient outcomesPatient concernsChemotherapy agentsCare modelProvider trainingSpecialty pharmacyClinical careClinical teamClinical supportDay 5PatientsDrug accessStaff satisfactionASCO PRO workgroup update: Patient-reported outcome measures as a quality indicator.
Stover A, Chiang A, Basch E. ASCO PRO workgroup update: Patient-reported outcome measures as a quality indicator. Journal Of Clinical Oncology 2016, 34: 276-276. DOI: 10.1200/jco.2016.34.7_suppl.276.Peer-Reviewed Original ResearchPatient-reported outcome measuresPRO measuresQuality of careOutcome measuresHospital readmission ratesCancer care deliveryPatient-centered approachSelf-reported symptomsHealth care decisionsEmetogenic chemotherapyPatient characteristicsReadmission ratesPatient questionnairePRO questionnairesLast visitHigher painPhysical functioningQuality useCare deliveryPractice settingsCare decisionsClinical usePatientsHealthcare experiencesUnderserved populations
2015
Final results of phase Ib of tarextumab (TRXT, OMP-59R5, anti-Notch2/3) in combination with etoposide and platinum (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC).
Pietanza M, Spira A, Jotte R, Gadgeel S, Mita A, Hart L, Gluck W, Chiang A, Liu S, Kapoun A, Xu L, Hill D, Dupont J, Spigel D, Zhou L. Final results of phase Ib of tarextumab (TRXT, OMP-59R5, anti-Notch2/3) in combination with etoposide and platinum (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC). Journal Of Clinical Oncology 2015, 33: 7508-7508. DOI: 10.1200/jco.2015.33.15_suppl.7508.Peer-Reviewed Original ResearchActivity and safety of pembrolizumab in patients with metastatic non-small cell lung cancer with untreated brain metastases.
Goldberg S, Gettinger S, Mahajan A, Herbst R, Chiang A, Tsiouris A, Vortmeyer A, Jilaveanu L, Speaker S, Madura M, Rowen E, Gerrish H, Knapp-Perry E, Yao X, Chiang V, Kluger H. Activity and safety of pembrolizumab in patients with metastatic non-small cell lung cancer with untreated brain metastases. Journal Of Clinical Oncology 2015, 33: 8035-8035. DOI: 10.1200/jco.2015.33.15_suppl.8035.Peer-Reviewed Original Research
2014
Development of Smilow's EPIC ambulatory dashboard and the impact on bar code scanning compliance at care centers.
Amport S, Shomsky L, Lyons C, Sterling R, Smith M, Beaulieu N, Corjulo D, Adelson K, Chiang A. Development of Smilow's EPIC ambulatory dashboard and the impact on bar code scanning compliance at care centers. Journal Of Clinical Oncology 2014, 32: 166-166. DOI: 10.1200/jco.2014.32.30_suppl.166.Peer-Reviewed Original Research